Thomas M Wisniewski

Summary

Affiliation: New York University School of Medicine
Country: USA

Publications

  1. pmc Amyloid-beta immunisation for Alzheimer's disease
    Thomas Wisniewski
    Department of Neurology, New York University School of Medicine, New York, NY 10016, USA
    Lancet Neurol 7:805-11. 2008
  2. ncbi request reprint Immunotherapy for Alzheimer's disease
    Thomas Wisniewski
    Departments of Neurology, New York University School of Medicine, Alexandria ERSP, 450 East 29th Street, New York, NY 10016, United States Departments of Pathology, New York University School of Medicine, Alexandria ERSP, 450 East 29th Street, New York, NY 10016, United States Departments of Psychiatry, New York University School of Medicine, Alexandria ERSP, 450 East 29th Street, New York, NY 10016, United States Electronic address
    Biochem Pharmacol 88:499-507. 2014
  3. pmc Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease
    Fernando Goni
    Department of Neurology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 5:e13391. 2010
  4. pmc Styryl-based and tricyclic compounds as potential anti-prion agents
    Erika Chung
    Department of Neurology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 6:e24844. 2011
  5. pmc Dissolution of pre-existing platelet thrombus by synergistic administration of low concentrations of bifunctional antibodies against β3 integrin
    Suying Dang
    Department of Medical Genetics, Shanghai Jiao Tong University School of Medicine, Shanghai, People s Republic of China
    PLoS ONE 6:e27012. 2011
  6. pmc Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models
    Fernando Goni
    Department of Neurology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    J Neuroinflammation 10:150. 2013
  7. pmc Could immunomodulation be used to prevent prion diseases?
    Thomas Wisniewski
    New York University School of Medicine, 560 First Avenue, New York, NY 10016, USA
    Expert Rev Anti Infect Ther 10:307-17. 2012
  8. pmc Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse
    Erika Chung
    Department of Neurology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    BMC Neurosci 11:130. 2010
  9. pmc Murine models of Alzheimer's disease and their use in developing immunotherapies
    Thomas Wisniewski
    Department of Neurology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Biochim Biophys Acta 1802:847-59. 2010
  10. pmc Immunomodulation for prion and prion-related diseases
    Thomas Wisniewski
    Department of Psychiatry, Millhauser Laboratories, Room HN419, New York University School of Medicine, 560 First Avenue, New York, NY 10016, USA
    Expert Rev Vaccines 9:1441-52. 2010

Research Grants

  1. AMYLOID BETA PEPTIDE AND THEIR BINDING PROTEINS
    Thomas Wisniewski; Fiscal Year: 1999
  2. Therapeutic Approaches for Prion Disease
    Thomas Wisniewski; Fiscal Year: 2007
  3. Detection and Clearance of AD Amyloid Lesions
    Thomas Wisniewski; Fiscal Year: 2007
  4. Detection and Clearance of AD Amyloid Lesions
    Thomas Wisniewski; Fiscal Year: 2009
  5. Amyloid beta Peptide and Apolipoprotein E
    Thomas Wisniewski; Fiscal Year: 2009
  6. Therapeutic Approaches for Prion Disease
    Thomas Wisniewski; Fiscal Year: 2009
  7. Therapeutic Approaches for Prion Disease
    Thomas M Wisniewski; Fiscal Year: 2010
  8. Therapeutic Approaches for Prion Disease
    Thomas Wisniewski; Fiscal Year: 2009
  9. Detection and Clearance of AD Amyloid Lesions
    Thomas M Wisniewski; Fiscal Year: 2010
  10. Amyloid beta Peptide and Apolipoprotein E
    Thomas Wisniewski; Fiscal Year: 2007

Collaborators

Detail Information

Publications51

  1. pmc Amyloid-beta immunisation for Alzheimer's disease
    Thomas Wisniewski
    Department of Neurology, New York University School of Medicine, New York, NY 10016, USA
    Lancet Neurol 7:805-11. 2008
    ..A delicate balance between immunological clearance of an endogenous protein with acquired toxic properties and the induction of an autoimmune reaction must be found...
  2. ncbi request reprint Immunotherapy for Alzheimer's disease
    Thomas Wisniewski
    Departments of Neurology, New York University School of Medicine, Alexandria ERSP, 450 East 29th Street, New York, NY 10016, United States Departments of Pathology, New York University School of Medicine, Alexandria ERSP, 450 East 29th Street, New York, NY 10016, United States Departments of Psychiatry, New York University School of Medicine, Alexandria ERSP, 450 East 29th Street, New York, NY 10016, United States Electronic address
    Biochem Pharmacol 88:499-507. 2014
    ..The design of future more effective immunomodulatory approaches will need to target all aspects of AD pathology, as well as specifically targeting pathological oligomeric conformers, without the use of any self-antigen. ..
  3. pmc Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease
    Fernando Goni
    Department of Neurology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 5:e13391. 2010
    ..This type of immunomodulation has the potential to be a universal β-sheet disrupter, which could be useful for the prevention or treatment of a wide range of neurodegenerative diseases...
  4. pmc Styryl-based and tricyclic compounds as potential anti-prion agents
    Erika Chung
    Department of Neurology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 6:e24844. 2011
    ..These four compounds can be considered, with further development, as candidates for prion therapy...
  5. pmc Dissolution of pre-existing platelet thrombus by synergistic administration of low concentrations of bifunctional antibodies against β3 integrin
    Suying Dang
    Department of Medical Genetics, Shanghai Jiao Tong University School of Medicine, Shanghai, People s Republic of China
    PLoS ONE 6:e27012. 2011
    ..025 µM (APAC + SLK vs APAC, p<0.05; APAC + SLK vs SLK, p<0.01). Thus these low concentrations of a combination of both agents are likely to be more effective and less toxic when used therapeutically in vivo...
  6. pmc Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models
    Fernando Goni
    Department of Neurology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    J Neuroinflammation 10:150. 2013
    ....
  7. pmc Could immunomodulation be used to prevent prion diseases?
    Thomas Wisniewski
    New York University School of Medicine, 560 First Avenue, New York, NY 10016, USA
    Expert Rev Anti Infect Ther 10:307-17. 2012
    ..The ongoing epidemic of chronic wasting disease affecting the USA and Korea, with the potential to spread to human populations, highlights the need for such immunomodulatory approaches...
  8. pmc Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse
    Erika Chung
    Department of Neurology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    BMC Neurosci 11:130. 2010
    ..At the conclusion of behavioral testing, animals were sacrificed and brain tissue was analyzed biochemically or immunohistochemically for the levels of amyloid plaques, PrPC, synaptophysin, Aβ40/42 and Aβ oligomers...
  9. pmc Murine models of Alzheimer's disease and their use in developing immunotherapies
    Thomas Wisniewski
    Department of Neurology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Biochim Biophys Acta 1802:847-59. 2010
    ..Because of these uncertainties, Tg models for AD are continuously being refined with the aim to better understand the disease and to enhance the predictive validity of potential treatments such as immunotherapies...
  10. pmc Immunomodulation for prion and prion-related diseases
    Thomas Wisniewski
    Department of Psychiatry, Millhauser Laboratories, Room HN419, New York University School of Medicine, 560 First Avenue, New York, NY 10016, USA
    Expert Rev Vaccines 9:1441-52. 2010
    ..Such approaches could have a significant impact on many of the common age-associated dementias...
  11. pmc Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models
    Thomas Wisniewski
    Department of Neurology, New York University School of Medicine, 550 First Avenue, New York, NY, 10016, USA
    Brain Struct Funct 214:201-18. 2010
    ..This is an essential goal since it will be necessary to develop therapeutic approaches which will be highly effective in humans...
  12. pmc Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors
    Thomas Wisniewski
    Department of Neurology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    BMC Neurosci 9:S5. 2008
    ..When combined with early pathology detection, these therapeutic strategies hold great promise as effective and relatively toxicity free methods of preventing AD related pathology...
  13. pmc Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages
    Ayodeji A Asuni
    Department of Psychiatry, New York University School of Medicine, Millhauser Laboratories, 560 First Avenue, New York, NY 10016, USA
    Eur J Neurosci 24:2530-42. 2006
    ..These findings indicate that our approach age-dependently improves cognition and reduces Abeta burden when used with an adjuvant suitable for humans, without increasing vascular Abeta deposits or microhemorrhages...
  14. ncbi request reprint Immunological and anti-chaperone therapeutic approaches for Alzheimer disease
    Thomas Wisniewski
    Department of Neurology, New York University School of Medicine, 550 First Avenue, NewYork, NY 10016, USA
    Brain Pathol 15:72-7. 2005
    ..In addition, the recent development of anti-chaperone therapy opens a new therapeutic avenue which is unlikely to be associated with toxicity...
  15. ncbi request reprint An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives
    Einar M Sigurdsson
    Department of Psychiatry, New York University School of Medicine, New York, New York 10016, USA
    J Neurosci 24:6277-82. 2004
    ..Our results indicate that these nontoxic Abeta derivatives produce an attenuated antibody response, which is less likely to be associated with negative side effects while having cognitive benefits...
  16. ncbi request reprint Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging
    Joseph F Poduslo
    Molecular Neurobiology Laboratory, Department of Neurology, Mayo Clinic Rochester, Minnesota 55905, USA
    Neurobiol Dis 11:315-29. 2002
    ..This could enable early diagnosis and also provide a direct measure of the efficacy of anti-amyloid therapies currently being developed...
  17. pmc Vaccination as a therapeutic approach to Alzheimer's disease
    Thomas Wisniewski
    Department of Neurology, New York University School of Medicine, New York, NY, USA
    Mt Sinai J Med 77:17-31. 2010
    ..In this review, we discuss the past experience with vaccination for Alzheimer's disease and the development of possible future strategies that target both amyloid beta-related and tau-related pathologies...
  18. pmc A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice
    Einar M Sigurdsson
    Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
    Neurobiol Aging 29:836-47. 2008
    ..3) Smaller, earlier plaques require contrast ligand for MRI visualization. Our ligand when combined with VBA may be useful for following therapeutic approaches targeting amyloid in transgenic mouse models...
  19. ncbi request reprint Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice
    Marcin Sadowski
    Department of Neurology, New York University School of Medicine, New York, New York 10016, USA
    J Neuropathol Exp Neurol 63:418-28. 2004
    ..5% +/- 0.4% at 8 months to 17.4% +/- 4.6%. These findings implicate Abeta or APP in the behavioral and metabolic impairments in APP/PS1 mice and the failure to compensate functionally for PS1-related hippocampal cell loss...
  20. pmc Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine
    Allal Boutajangout
    Department of Physiology and Neuroscience, New York University School of Medicine, New York, NY 10016, USA
    J Alzheimers Dis 18:961-72. 2009
    ..These results further support our findings with this immunogen delivered subcutaneously and demonstrate its efficacy when given orally, which may provide added benefits for human use...
  21. ncbi request reprint A safer vaccine for Alzheimer's disease?
    Einar M Sigurdsson
    Department of Psychiatry, School of Medicine, New York University, 550 First Avenue, New York 10016, USA
    Neurobiol Aging 23:1001-8. 2002
    ..Future Abeta derived vaccines should include T(h) epitopes, carriers and/or lipid moieties to enhance antibody production in the elderly, the population predominantly affected by AD...
  22. ncbi request reprint Styryl-based compounds as potential in vivo imaging agents for beta-amyloid plaques
    Qian Li
    Department of Chemistry, New York University, School of Medicine, New York, NY 11219, USA
    Chembiochem 8:1679-87. 2007
    ..A representative compound, STB-8, was used in ex vivo and in vivo imaging experiments on an AD transgenic mouse model and demonstrated excellent blood-brain barrier (BBB) permeability and specific staining of the AD beta-amyloid plaques...
  23. ncbi request reprint Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging
    Youssef Zaim Wadghiri
    Skirball Institute of Biomolecular Medicine, New York University School of Medicine, New York, New York 10016, USA
    Magn Reson Med 50:293-302. 2003
    ..This approach provides an in vivo method to detect Abeta in AD transgenic mice, and suggests that diagnostic MRI methods to detect Abeta in AD patients may ultimately be feasible...
  24. ncbi request reprint Vaccines for conformational disorders
    Marcin Sadowski
    Department of Neurology, New York University School of Medicine, 550 First Avenue, MHL Rm HN 419, New York, NY 10016, USA
    Expert Rev Vaccines 3:279-90. 2004
    ..Novel vaccine strategies are under development for both Alzheimer's disease and prionoses which are predicted to have few or no significant side effects, while being efficacious...
  25. ncbi request reprint Links between the pathology of Alzheimer's disease and vascular dementia
    Marcin Sadowski
    Department of Neurology, New York University School of Medicine, New York, New York 10016, USA
    Neurochem Res 29:1257-66. 2004
    ..In this paper, we review some of the links between vascular risk factors and AD pathology and present data on the direct effect of ischemia on cognitive function and A beta deposition in a mouse model of AD...
  26. pmc Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease
    Martin J Sadowski
    Department of Neurology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Proc Natl Acad Sci U S A 103:18787-92. 2006
    ..Furthermore, behavioral studies demonstrated that treatment with Abeta12-28P prevents a memory deficit in transgenic animals. These findings provide evidence of another therapeutic approach for AD...
  27. pmc Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging
    Henrieta Scholtzova
    Department of Neurology, New York University School of Medicine, New York, New York 10016, USA
    J Neurosci Res 86:2784-91. 2008
    ..In addition, our study shows, for the first time, the utility of micro MRI in conjunction with gadolinium-labeled A beta labeling agents to monitor the therapeutic response to amyloid-reducing agents...
  28. pmc Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology
    Henrieta Scholtzova
    Department of Neurology, New York University School of Medicine, New York, New York 10016, USA
    J Neurosci 29:1846-54. 2009
    ..Our data suggest that stimulation of innate immunity via TLR9 is highly effective at reducing the parenchymal and vascular amyloid burden, along with Abeta oligomers, without apparent toxicity...
  29. ncbi request reprint Targeting prion amyloid deposits in vivo
    Marcin Sadowski
    Department of Neurology, New York University School of Medicine, New York, New York 10016, USA
    J Neuropathol Exp Neurol 63:775-84. 2004
    ..These results suggest that methoxy-X04 or similar derivatives could be used as PET imaging agents to improve the diagnosis of human prion diseases associated with amyloid deposition...
  30. pmc A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice
    Marcin Sadowski
    Department of Neurology, New York University School of Medicine, New York, New York, USA
    Am J Pathol 165:937-48. 2004
    ..Our experiments demonstrate that compounds blocking the interaction between Abeta and its pathological chaperones may be beneficial for treatment of beta-amyloid deposition in AD...
  31. ncbi request reprint Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult mice
    Paul H Wen
    Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029, USA
    Neurobiol Dis 10:8-19. 2002
    ..These studies suggest that PS-1 plays a role in regulating neurogenesis in adult hippocampus and that FAD mutants may have deleterious properties independent of their effects on amyloid deposition...
  32. pmc Anti-PrP Mab 6D11 suppresses PrP(Sc) replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo
    Martin J Sadowski
    Department of Neurology, New York University School of Medicine, NY 10016, USA
    Neurobiol Dis 34:267-78. 2009
    ..Our results indicate that antibody-based therapeutic strategies can be used, even on a short-term basis, to delay or prevent disease in subjects accidentally exposed to prions...
  33. pmc Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration
    Jerzy Wegiel
    Department of Developmental Neurobiology, NYS Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY, 10314, USA
    Acta Neuropathol 113:389-402. 2007
    ....
  34. ncbi request reprint Immunization treatment approaches in Alzheimer's and prion diseases
    Thomas Wisniewski
    Department of Neurology, New York University Medical Center, Millhauser Laboratory, HN419, 550 First Avenue, New York, NY 10016, USA
    Curr Neurol Neurosci Rep 2:400-4. 2002
    ..These immune-based treatment approaches have great potential as rational therapies for this devastating group of disorders, but additional development is needed before they can be safely applied to humans...
  35. ncbi request reprint Disease modifying approaches for Alzheimer's pathology
    Marcin Sadowski
    Department of Neurology, New York University School of Medicine, New York, NY 10016, USA
    Curr Pharm Des 13:1943-54. 2007
    ..Pre-clinical data suggests that it will be much more feasible to prevent AD related pathology, then to clear existing pathology, making early diagnosis critically important...
  36. ncbi request reprint Therapeutic approaches for prion and Alzheimer's diseases
    Thomas Wisniewski
    Department of Neurology, New York University School of Medicine, NY 10016, USA
    FEBS J 274:3784-98. 2007
    ..Therefore, there is a great need for effective therapies for both Alzheimer's disease and prion diseases...
  37. ncbi request reprint Infectivity of amyloid diseases
    Einar M Sigurdsson
    Department of Psychiatry, New York University, School of Medicine, 560 First Avenue, New York, NY 10016, USA
    Trends Mol Med 8:411-3. 2002
    ..Thus, amyloid-related therapeutic approaches should not be based on administration of amyloidogenic peptides in conjunction with an inflammatory stimulus, such as in a recently halted clinical trial for Alzheimer's disease...
  38. ncbi request reprint Magnetic resonance imaging of amyloid plaques in transgenic mice
    Youssef Zaim Wadghiri
    Skirball Institute of Biomolecular Medicine and Department of Radiology, New York University School of Medicine, NY, USA
    Methods Mol Biol 299:365-79. 2005
    ....
  39. doi request reprint Prominent neuroleptic sensitivity in a case of early-onset Alzheimer disease due to presenilin-1 G206A mutation
    Steven P Cercy
    Memory Disorders Clinic, Veterans Affairs New York Harbor Healthcare System, New York, NY 10010, USA
    Cogn Behav Neurol 21:190-5. 2008
    ..We describe atypical motor and cognitive features in a case of familial Alzheimer disease (FAD) due to presenilin-1 (PS-1) mutation...
  40. ncbi request reprint Ligand binding and calcium influx induce distinct ectodomain/gamma-secretase-processing pathways of EphB2 receptor
    Claudia Litterst
    Department of Psychiatry and Neuroscience, Mount Sinai School of Medicine New York University, New York, NY 10029, USA, and Institute for Molecular Cardiovascular Research, University Hospital Reinisch West Faelische Technische Hochschule, Aachen, Germany
    J Biol Chem 282:16155-63. 2007
    ..Our data identify novel cleavages and modifications of EphB2 receptor and indicate that specific conditions determine the proteolytic systems and subcellular sites involved in the processing of this receptor...
  41. pmc Immunization delays the onset of prion disease in mice
    Einar M Sigurdsson
    Department of Psychiatry, New York University School of Medicine, New York, New York 10016, USA
    Am J Pathol 161:13-7. 2002
    ..The increase in the incubation period closely correlated with the anti-prion protein antibody titer. This promising finding suggests that a similar approach may work in humans or other mammalian species at risk for prion disease...
  42. pmc An entorhinal cortex sulcal pattern is associated with Alzheimer's disease
    Jiong Zhan
    Department of Psychiatry, New York University School of Medicine, New York 10016, USA
    Hum Brain Mapp 30:874-82. 2009
    ..We classified the lateral EC sulcal boundary as either a rhinal or collateral pattern and tested the hypotheses that the rhinal pattern was (1) more common in AD and (2) associated with a smaller EC size...
  43. pmc FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease
    Lisa Mosconi
    Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
    Eur J Nucl Med Mol Imaging 36:811-22. 2009
    ....
  44. ncbi request reprint Plaque-associated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology
    Maria C Leal
    Fundacion Instituto Leloir, Instituto de Investigaciones Bioquímicas de Buenos Aires, CONICET, Ciudad de Buenos Aires, Argentina
    J Neuropathol Exp Neurol 65:976-87. 2006
    ..We propose that in Tg2576 mice and in contrast to its behavior in Alzheimer brains, active IDE increases with age around plaques as a component of astrocyte activation as a result of Abeta-triggered inflammation...
  45. pmc Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization
    Igor Klyubin
    Institute of Neuroscience and Department of Pharmacology and Therapeutics, Trinity College, Dublin 2, Ireland
    J Neurosci 28:4231-7. 2008
    ..Abeta monomer isolated from human CSF did not affect long-term potentiation. These results strongly support a strategy of passive immunization against soluble Abeta oligomers in early Alzheimer's disease...
  46. ncbi request reprint A novel highly pathogenic Alzheimer presenilin-1 mutation in codon 117 (Pro117Ser): Comparison of clinical, neuropathological and cell culture phenotypes of Pro117Leu and Pro117Ser mutations
    Wieslaw K Dowjat
    Institute for Basic Research in Developmental Disabilities, Staten Island, New York 10314, USA
    J Alzheimers Dis 6:31-43. 2004
    ..Given the high potency in vivo and in vitro of both codon 117 mutations, this site of PS1 must be particularly important for its normal/pathogenic function...
  47. ncbi request reprint MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease
    Joseph A Helpern
    Nathan S Kline Institute, Orangeburg, New York 10962, USA
    Magn Reson Med 51:794-8. 2004
    ..No differences in T(1) values or proton density were detected between any groups of mice. These results indicate that T(2) may be a sensitive marker of abnormalities in this transgenic mouse model of AD...
  48. ncbi request reprint Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions
    Jasmina B Mackic
    Department of Neurological Surgery, USC School of Medicine, Los Angeles, CA 90033, USA
    Vascul Pharmacol 38:303-13. 2002
    ..Negligible capillary binding, rapid systemic and brain degradation, and accelerated body elimination of blood-borne A beta, may prevent the development of CAA in rhesus in contrast to squirrel monkeys...
  49. pmc An aggregation-specific enzyme-linked immunosorbent assay: detection of conformational differences between recombinant PrP protein dimers and PrP(Sc) aggregates
    Tao Pan
    Institute of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH 44107 1712, USA
    J Virol 79:12355-64. 2005
    ..Finally, the principle of the aggregate-specific ELISA we have developed may be applicable to other diseases caused by abnormal protein aggregation, such as Alzheimer's disease or Parkinson's disease...
  50. pmc 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease
    Omidreza Firuzi
    Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA 19140, USA
    FASEB J 22:1169-78. 2008
    ..Our work suggests that pharmacological inhibition of 5LO could provide a novel therapeutic tool for AD...

Research Grants28

  1. AMYLOID BETA PEPTIDE AND THEIR BINDING PROTEINS
    Thomas Wisniewski; Fiscal Year: 1999
    ..We will also identify if any of these labeled peptides are deposited on the Abeta lesions, in vivo. The latter could be used to develop a diagnostic test for AD. ..
  2. Therapeutic Approaches for Prion Disease
    Thomas Wisniewski; Fiscal Year: 2007
    ..In vivo imaging will also be done with 2 photon microscopy and non-toxic, Congo red analogs. Our novel imaging techniques will be used to monitor our therapeutic experiments. ..
  3. Detection and Clearance of AD Amyloid Lesions
    Thomas Wisniewski; Fiscal Year: 2007
    ..Lay Summary: Active vaccination is an potential exciting therapy for AD; however, it can only be applied to patients if effective methods which are non-toxic can be developed. This application seeks to verify if this is possible. ..
  4. Detection and Clearance of AD Amyloid Lesions
    Thomas Wisniewski; Fiscal Year: 2009
    ..Lay Summary: Active vaccination is an potential exciting therapy for AD; however, it can only be applied to patients if effective methods which are non-toxic can be developed. This application seeks to verify if this is possible. ..
  5. Amyloid beta Peptide and Apolipoprotein E
    Thomas Wisniewski; Fiscal Year: 2009
    ..These studies will test our central hypothesis that blocking the Aa/apoE interaction can serve as a novel, non-toxic therapeutic target for Alzheimer's disease. ..
  6. Therapeutic Approaches for Prion Disease
    Thomas Wisniewski; Fiscal Year: 2009
    ..This proposal aims to develop both active and passive immunization approaches to both prevent infection and to treat symptomatic disease in animal and human populations, respectively. ..
  7. Therapeutic Approaches for Prion Disease
    Thomas M Wisniewski; Fiscal Year: 2010
    ..This proposal aims to develop both active and passive immunization approaches to both prevent infection and to treat symptomatic disease in animal and human populations, respectively. ..
  8. Therapeutic Approaches for Prion Disease
    Thomas Wisniewski; Fiscal Year: 2009
    ..This competitive revision proposal aims to develop active vaccination in mule deer to prevent the spread of CWD in animals, reducing the possibility of CWD infecting humans. ..
  9. Detection and Clearance of AD Amyloid Lesions
    Thomas M Wisniewski; Fiscal Year: 2010
    ..Lay Summary: Active vaccination is an potential exciting therapy for AD;however, it can only be applied to patients if effective methods which are non-toxic can be developed. This application seeks to verify if this is possible. ..
  10. Amyloid beta Peptide and Apolipoprotein E
    Thomas Wisniewski; Fiscal Year: 2007
    ..These studies will test our central hypothesis that blocking the Aa/apoE interaction can serve as a novel, non-toxic therapeutic target for Alzheimer's disease. ..
  11. Amyloid beta Peptide and Apolipoprotein E
    Thomas Wisniewski; Fiscal Year: 2006
    ..These studies will test our central hypothesis that blocking the Aa/apoE interaction can serve as a novel, non-toxic therapeutic target for Alzheimer's disease. ..
  12. AMYLOID BETA PEPTIDE AND THEIR BINDING PROTEINS
    Thomas Wisniewski; Fiscal Year: 2000
    ..We will also identify if any of these labeled peptides are deposited on the Abeta lesions, in vivo. The latter could be used to develop a diagnostic test for AD. ..
  13. AMYLOID BETA PEPTIDE AND THEIR BINDING PROTEINS
    Thomas Wisniewski; Fiscal Year: 2001
    ..We will also identify if any of these labeled peptides are deposited on the Abeta lesions, in vivo. The latter could be used to develop a diagnostic test for AD. ..
  14. Detection and Clearance of AD Amyloid Lesions
    Thomas Wisniewski; Fiscal Year: 2002
    ..Our preliminary results indicate that APP/PS1 Tg aged mice have significant cognitive impairments versus controls. These studies will provide essential information before such approach can be safely used in humans. ..
  15. AMYLOID BETA PEPTIDE AND THEIR BINDING PROTEINS
    Thomas Wisniewski; Fiscal Year: 2002
    ..We will also identify if any of these labeled peptides are deposited on the Abeta lesions, in vivo. The latter could be used to develop a diagnostic test for AD. ..
  16. Detection and Clearance of AD Amyloid Lesions
    Thomas Wisniewski; Fiscal Year: 2003
    ..Our preliminary results indicate that APP/PS1 Tg aged mice have significant cognitive impairments versus controls. These studies will provide essential information before such approach can be safely used in humans. ..
  17. Detection and Clearance of AD Amyloid Lesions
    Thomas Wisniewski; Fiscal Year: 2004
    ..Our preliminary results indicate that APP/PS1 Tg aged mice have significant cognitive impairments versus controls. These studies will provide essential information before such approach can be safely used in humans. ..
  18. Therapeutic Approaches for Prion Disease
    Thomas Wisniewski; Fiscal Year: 2004
    ..In vivo imaging will also be done with 2 photon microscopy and non-toxic, Congo red analogs. Our novel imaging techniques will be used to monitor our therapeutic experiments. ..
  19. Detection and Clearance of AD Amyloid Lesions
    Thomas Wisniewski; Fiscal Year: 2005
    ..Our preliminary results indicate that APP/PS1 Tg aged mice have significant cognitive impairments versus controls. These studies will provide essential information before such approach can be safely used in humans. ..
  20. Therapeutic Approaches for Prion Disease
    Thomas Wisniewski; Fiscal Year: 2005
    ..In vivo imaging will also be done with 2 photon microscopy and non-toxic, Congo red analogs. Our novel imaging techniques will be used to monitor our therapeutic experiments. ..
  21. Amyloid beta Peptide and Apolipoprotein E
    Thomas Wisniewski; Fiscal Year: 2005
    ..These studies will test our central hypothesis that blocking the Aa/apoE interaction can serve as a novel, non-toxic therapeutic target for Alzheimer's disease. ..
  22. Detection and Clearance of AD Amyloid Lesions
    Thomas Wisniewski; Fiscal Year: 2006
    ..Our preliminary results indicate that APP/PS1 Tg aged mice have significant cognitive impairments versus controls. These studies will provide essential information before such approach can be safely used in humans. ..
  23. Therapeutic Approaches for Prion Disease
    Thomas Wisniewski; Fiscal Year: 2006
    ..In vivo imaging will also be done with 2 photon microscopy and non-toxic, Congo red analogs. Our novel imaging techniques will be used to monitor our therapeutic experiments. ..
  24. Therapeutic Targeting of Abnormal Conformation in Neurodegenerative Disease
    Thomas M Wisniewski; Fiscal Year: 2010
    ..The most toxic conformers are the oligomeric forms, which we plan to target by developing novel approaches to both increase their clearance and to reduce their toxicity. ..